I’m excited to see that a company has a promising treatment for brain tumors, but I’m worried that they’re using Gadolinium since that drug can cause Nephrogenic Systemic Fibrosis (NSF) in people with renal problems:
"Enrollment in two Phase 2 trials with motexafin gadolinium for adult brain tumors and childhood gliomas also continues under sponsorship of the National Cancer Institute and we are planning to conduct a pivotal Phase 3 trial with motexafin gadolinium in patients with brain metastases from lung cancer. Our strategy is to build value in these multiple products as we progress with their development."
Source: Pharmacyclics, Inc. Reports Fourth Quarter and Fiscal 2008 Financial Results
Let’s hope that this company properly screens test subjects.
Here is some more information about Gadolinium and Nephrogenic Systemic Fibrosis for you to consider.